Last reviewed · How we verify
Chimeric anti-CD20 monoclonal antibody — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Chimeric anti-CD20 monoclonal antibody (Chimeric anti-CD20 monoclonal antibody) — Sinocelltech Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chimeric anti-CD20 monoclonal antibody TARGET | Chimeric anti-CD20 monoclonal antibody | Sinocelltech Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chimeric anti-CD20 monoclonal antibody CI watch — RSS
- Chimeric anti-CD20 monoclonal antibody CI watch — Atom
- Chimeric anti-CD20 monoclonal antibody CI watch — JSON
- Chimeric anti-CD20 monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). Chimeric anti-CD20 monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/chimeric-anti-cd20-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab